Prospective observational study of Idiopathic pulmonary fibrosis with Non-small-cell lung cancer(LOGIK0603)
- Conditions
- Idiopathic pulmonary fibrosis
- Registration Number
- JPRN-UMIN000015929
- Lead Sponsor
- ung Oncology Group in Kyushu, Japan (LOGIK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Not provided
1) Patients with suspicion of exacerbation of idiopathic pulmonary fibrosis (increase in such as LDH, KL-6, SP-A, SP-D, so on). 2) Patient with superior vena cava syndrome. 3) Patient with the history of severe drug allergy. 4) Patient with pleural effusion, ascites, and pericardial effusion need for treatment of such as drainage. 5) Patient with severe infection and other severe complications (gastrointestinal hemorrhage, heart disease, etc). 6) Patient with symptomatic brain metastasis. 7) Patients with steroid administration. 8) Patient with active double cancer. 9) Patient with diabetes hard to control. 10) Unstable psychic disorder. 11) Pregnant or breast-feeding females. 12) Inappropriate patients for this study judged by the physicians. In group B, to confirm hypersensitivity to polyoxyethylene castor oil (Cremophor EL) product (such as cyclosporine), curing caster oil product (such as injectable vitamin), and alcohol hypersensitivity.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Frequency of acute exacerbation of idiopathic pulmonary fibrosis
- Secondary Outcome Measures
Name Time Method Frequency of acute exacerbation of idiopathic pulmonary fibrosis and death rate about the patient treated with anticancer drug. Grading and frequency of other adverse event (CTCAE ver.3.0 Japanese edition/JCOG/JSCO) and response rate.